Previous 10 | Next 10 |
Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q3 2021 Earnings Call Nov 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q3 - Results - Earnings Call Presentation
TherapeuticsMD, Inc. (TXMD) Q3 Earnings Conference Call November 11, 2021, 08:30 AM ET Company Participants Lisa Wilson – Investor Relations Rob Finizio – Chief Executive Officer Hugh O’Dowd – President James D'Arecca – Chief Financial Officer Mark Glickman ...
TherapeuticsMD (NASDAQ:TXMD) has announced a new cost savings initiative designed to save at least $40M beginning in 2022. The company also says it will save $20M annually due to the divestiture of vitaCare. In Q3 2021, TherapeuticsMD's net loss widened ~45% to $47.4M (-$0.11 per basic and di...
Therapeutics MD (NASDAQ:TXMD): Q3 GAAP EPS of -$0.11 misses by $0.01. Revenue of $25.4M (+31.3% Y/Y) misses by $0.47M. Shares +3.35% PM. Press Release As of September 30, 2021, the Company’s cash on hand totaled $104.8M, compared with $80.5M as of December 31, 2020 For further detail...
- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA ® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximatel...
- Mr. O’Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading women’s healthcare company, today announced...
Therapeutics MD (NASDAQ:TXMD) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $25.87M (+33.8% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of t...
AEG, OTCQX:ALEAF, AMTX, AYRO, AZUL, BAM, BGRY, CAE, CELH, OTCQX:CRLBF, DCBO, OTCQX:EDVMF, GRWG, HUT, IMV, OTCPK:MKGAF, NICE, NVVE, OGN, PSFE, QSI, RSLS, RWLK, SBH, SPCB, SPH, STNG, STXS, THRY, TMDI, TPR, TXMD, UTZ, VNRX, WB, WIX, WWR, XNET, YETI For Seeking Alpha's full earnings season calend...
Are These Penny Stocks A Buy Or Avoid Right Now? If you’re like most retail traders right now, you’re on the hunt for the next round of hot penny stocks to buy. In the stock market today, meme stocks are heating up. What some may consider the “OG” or bell...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...